Business Inquiry
Global:
Email:marketing@medicilon.com
+1(781)535-1428(U.S.)
0044 7790 816 954 (Europe)
China:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
Patient-derived xenograft or PDX model is now recognized as the good in vivo model for predicting clinical outcomes. It is derived by growing a fragment of patient tumor tissue on immuno-deficient mice, which faithfully recapitulates the genomic, phenotypic and molecular biological complexities found in the cancer tissue of origin.